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OBJECTIVE — Low-gradechronicinﬂammationhasbeenhypothesizedtounderlietheconstel-
lationofcardiometabolicriskfactors,possiblybyinducinginsulinresistance.Inthepresentstudy,we
investigatedassociationsbetweeninﬂammationmarkers,insulinsensitivity(expressedastheratioof
theMvaluetothemeanplasmainsulinconcentrationsmeasuredduringtheﬁnal40minoftheclamp
[M/I]), and a range of cardiometabolic risk factors in a large, healthy population.
RESEARCHDESIGNANDMETHODS — TheRelationshipbetweenInsulinSensitivity
and Cardiovascular Disease (RISC) cohort includes 1,326 nondiabetic European men and
women, aged between 30 and 60 years. We measured cardiometabolic risk factors and per-
formed a hyperinsulinemic-euglycemic clamp. We determined total white blood cell count
(WBC) and erythrocyte sedimentation rate (ESR) as markers of chronic inﬂammation.
RESULTS — WBC and ESR were both strongly associated with M/I. WBC and ESR were
further associated with a range of cardiometabolic risk factors. Associations between WBC and
HDL cholesterol, triglycerides, heart rate, fasting C-peptide, and insulin and 2-h insulin in men
and women and between WBC and 2-h glucose in women remained signiﬁcant after adjustment
forbothM/Iandwaistcircumference.AssociationsbetweenESRandHDLcholesterol,heartrate,
fasting, and 2-h insulin in men and women and between ESR and fat mass in women remained
signiﬁcant after adjustment for M/I and waist circumference.
CONCLUSIONS — This study showed that low-grade chronic inﬂammation is associated
with the cardiometabolic risk proﬁle of a healthy population. Insulin resistance, although
strongly associated with inﬂammation, does not seem to play a large intermediary role.
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S
everal inﬂammation markers have
been shown to be associated with
cardiometabolic risk proﬁle. A
study in a diabetic population showed
that abnormalities of the immune system
including elevated levels of acute-phase
reactants, interleukin-6 (IL-6), C-reactive
protein (CRP), and cortisol were all asso-
ciated with the metabolic syndrome (1).
The Insulin Resistance Atherosclerosis
Study (IRAS) showed in a nondiabetic
population that white blood cell count
(WBC), CRP, and ﬁbrinogen were all re-
lated to elements of the metabolic syn-
drome (2). In a range of prospective
studies, inﬂammation markers have also
been shown to relate to the development
of type 2 diabetes and coronary heart
disease.TheAtherosclerosisRiskinCom-
munities (ARIC) study reported associa-
tions between raised WBC, ﬁbrinogen,
and low serum albumin and diagnosis of
diabetes 7 years later in a large middle-
aged population (3). In a large cohort
study in patients undergoing angiogra-
phy, the erythrocyte sedimentation rate
(ESR) was related to coronary atheroscle-
rosis and was a predictor of cardiac death
in patients with probable ischemic heart
disease (4). A meta-analysis of prospec-
tive studies investigating the relationship
between inﬂammatory factors and subse-
quent coronary heart disease showed as-
sociations between ﬁbrinogen, CRP,
albumin, and WBC and the development
of coronary heart disease (5).
Low-grade inﬂammation may lead to
cardiometabolic disease by inducing in-
sulin resistance, a major contributor to
the development of cardiovascular and
metabolic disease. Insulin resistance has
been shown to be associated with several
inﬂammatory factors (2,6,7). A prospec-
tive study in Pima Indians showed that a
high WBC predicted development of dia-
betes, independent of body fat (8). The
effect seemed to be mediated by a wors-
ening of insulin sensitivity during the 5
years of follow-up.
Limitations of the existing literature
on the association between low-grade in-
ﬂammation, insulin resistance, and car-
diometabolic disease include the lack of
direct measurement of insulin sensitivity
by the standard technique, the hyperin-
sulinemic-euglycemic clamp, in a large
healthy population. Often, fasting hyper-
insulinemia has been used as a surrogate
measure of insulin sensitivity (6,7). How-
ever, along with others, our group has
shown that hyperinsulinemia contributes
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insulin resistance as measured by the hy-
perinsulinemic-euglycemic clamp (9).
The question is whether low-grade inﬂam-
mation is associated with insulin sensitivity
as measured by the hyperinsulinemic-
euglycemic clamp and whether clamp-
derived insulin resistance mediates the
association between inﬂammation and car-
diometabolic disease. In the present study
we tried to answer these questions by using
data from the Relationship between Insulin
Sensitivity and Cardiovascular Disease
(RISC) study cohort.
RESEARCH DESIGN AND
METHODS— The RISC cohort con-
sists of clinically healthy men and women
aged between 30 and 60 years. Cohort
members were recruited by 19 research
centers in 14 European countries. De-
tailed information on inclusion can be
found elsewhere (10). The local medical
ethics committee of each participating re-
searchcenterapprovedthestudy.Allpar-
ticipants gave written informed consent.
Basal measurements
As indicators for cardiometabolic disease
risk, we included waist circumference, fat
mass, fasting glucose, proinsulin, insulin
and C-peptide, 2-h glucose and insulin, in-
sulin resistance, HDL cholesterol, triglycer-
ides,systolicbloodpressure(SBP),diastolic
blood pressure (DBP), and heart rate.
Wemeasuredheightonaclinicstadi-
ometer, weight and fat-free mass with the
Tanita bioimpedance balance (Tanita,
Middlesex, U.K.), and waist circumfer-
ence with a tape measure. Blood pressure
and heart rate were measured three times
by an automatic blood pressure measur-
ing device (OMRON, Hoofddorp, the
Netherlands). We used the median value
of the three measurements. Fasting blood
samples were taken to assess WBC, ESR,
and lipids. We performed a 75-g oral glu-
cosetolerancetest(OGTT).Alifestyleand
medicalhistoryquestionnairewasusedto
collectinformationonsocioeconomicsta-
tus, family history of diabetes, smoking
and alcohol drinking habits, and physical
activity.
Insulin sensitivity
On a separate day within 1 month of the
OGTT, a hyperinsulinemic-euglycemic
clamp was performed in all participants
included in the study. Fasting samples
were taken to assess proinsulin and C-
peptide.Exogenousinsulinwasinfusedat
a rate of 240 pmol   min
–1   m
–2 simulta-
neously with a 20% dextrose infusion.
Plasma glucose was measured at 5- to 10-
min intervals to ensure that it remained
within 0.8 mmol/l (15%) of the target
glucose concentration (4.5–5.0 mmol/l).
Thesteady-stateperiodforthecalculation
of the M value was between 80 and 120
min and normalized by the fat-free mass.
Insulin sensitivity was expressed as the
ratio of the M value to the mean plasma
insulin concentrations measured during
theﬁnal40minoftheclamp(M/I)(9).All
clamps were performed between June
2002 and October 2004.
Laboratory measurements
Both WBC and ESR were determined in
local laboratories cooperating with each
participating research center. Total WBC
was measured by automated cell counters.
ESR was measured by the modiﬁed West-
ergren method. The mean all-center vari-
ance of the WBC was 2.8  10
12/l and of
ESR was 52.5 mm/h, whereas the be-
tween-center variances were 0.2  10
12/l
and 52.5 mm/h. All other variables were
measured by a central laboratory. De-
tailed information on further laboratory
assessments can be found elsewhere (9).
Statistical methods
Fat mass was calculated by subtracting
fat-freemassfromtotalbodyweight.Vari-
ables with skewed distributions are rep-
resented by medians and interquartile
ranges and were log-transformed when
used in a multivariate regression analysis.
Because of large sex differences in ESR
values, we performed all analyses and
show all data separately for men and
women. We split the cohort according to
sex-speciﬁc quartiles of WBC concentra-
tions and ESR values.
Weusedlogisticandlinearregression
analysis to analyze possible differences
betweenthequartilesongeneral,lifestyle,
and clinical characteristics. We used
Spearman’s  to analyze correlations be-
tweenWBCandESR,M/I,andthecardio-
metabolic risk factors. To detect possible
effects of infections, we analyzed correla-
tionsagainafterexclusionofclinicallyab-
normal WBC values (10  10
12/l) and
ESR (15 mm/h). Finally, we used linear
regression analysis to study the associa-
tions between WBC, ESR, insulin sensi-
tivity, and cardiometabolic risk factors.
We ran four models: in the ﬁrst model we
adjustedforthebasicvariablesage,smok-
ing, and study center; in the second
model we adjusted for the basic variables
and waist circumference; in the third
model we adjusted for the basic variables
and M/I; and in the fourth model we ad-
justed for the basic variables, waist cir-
cumference, and M/I. In all other
statistical models, we adjusted for age,
smoking, and study center. To make the
resultingregressioncoefﬁcientscompara-
ble, we report standardized  values.
RESULTS
Study group
A total of 1,538 men and women partici-
pated in the RISC cohort. After the basal
measurements, 180 cohort members not
satisfying the inclusion criteria were ex-
cluded and 32 participants dropped out.
We excluded another 13 participants, be-
cause both WBC and ESR values were
missing. Of the resulting group of 1,313
participants, 591 (45%) were men. The
mean  SD age of the study group was
43.8  8.3 years (Table 1).
WBC, ESR, and general and lifestyle
characteristics
Median values and interquartile ranges
for WBCs were 5.5 (2.2)  10
12/l in men
and 5.8 (2.0)  10
12/l in women (P 
0.73 for difference). Median values and
interquartilerangesforESRwere5.0(7.0)
mm/h in men and 8.0 (8.0) mm/h in
women (P  0.01 for difference).
In men, there was a positive associa-
tion between age and WBC that showed a
trend toward signiﬁcance (P  0.07),
whereas in women the association was
statistically signiﬁcant (P  0.01). Smok-
ingstatus(P0.01)wassigniﬁcantlyand
positively associated with WBC in men
and women. Study center was associated
with WBC in men only (P  0.01). ESR
was signiﬁcantly associated with study
center (P  0.01) and negatively associ-
ated with alcohol intake (P  0.01) in
both men and women. Medians for WBC
for the different study centers ranged
from 4.5 to 7.4  10
12/l in men and from
4.9to6.410
12/linwomen.Mediansfor
ESR ranged from 2.0 to 9.0 mm/h in men
and from 5.0 to 15.0 mm/h in women.
WBC and ESR were signiﬁcantly corre-
latedwitheachotherandwerestrongerin
men (0.14, P  0.01) than in women
(0.08, P  0.04).
WBC, ESR, and M/I
WBC was negatively correlated with M/I in
both men (–0.19, P  0.01) and
women (–0.10, P  0.01) (Table 2).
Per unit increase in WBC, M/Idecreased by
6.7% (95% CI 4.2–9.3, adjusted for age,
Inﬂammation, insulin, and cardiometabolic risk
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4.3% (2.1–6.5) in women. Additional ad-
justment for waist circumference led to a
M/I decrease of 4.5% (2.1–6.8) per unit
WBC in men and 3.2% (1.0–5.3) in
women.
ESR was also negatively correlated
with M/I in men (–0.27, P  0.01)
andwomen(–0.21,P0.01)(Table
3). M/I decreased by 2.1% (95% CI 1.3–
2.9) per unit increase in ESR in men and
by 1.2% (0.8–1.6) in women. With ad-
justment for waist circumference, the de-
crease was 1.3% (0.6–2.0) in men and
0.9% (0.5–1.3) in women.
WBC, cardiometabolic risk factors,
and M/I
Correlations between WBC and all car-
diometabolic risk factors except SBP,
DBP, fasting glucose in both men and
women, and 2-h glucose in men were sig-
niﬁcant (Table 2). Overall, correlations
werestrongerinmenthaninwomen.Ina
multivariableregressionmodel,WBCwas
a statistically signiﬁcant predictor vari-
able for waist circumference, fat mass,
HDL cholesterol, triglycerides, heart rate,
2-hglucose,fastingC-peptide,proinsulin
and insulin, 2-h insulin, and M/I in men
and in women and also for dBP in
women (adjusted for age, study center,
and smoking). After addition of M/I to
the regression model, associations be-
tween WBC and 2-h glucose and fasting
proinsulin in men and between WBC and
DBP in women became statistically nonsig-
niﬁcant. Associations between WBC and
HDL cholesterol, triglycerides, heart rate,
fastingC-peptide,andinsulinand2-hinsu-
lin in men and women and between WBC
and2-hglucoseinwomenremainedsignif-
icant after adjustment for both M/I and
waist circumference.
ESR, cardiometabolic risk factors,
and M/I
Correlations between ESR and all cardio-
metabolic risk factors but fasting glucose
in men and women and sBP, dBP, and
fasting proinsulin in men were signiﬁcant
(Table 3). In a multivariable regression
model, ESR was a statistically signiﬁcant
predictor variable for waist circumfer-
ence,fatmass,HDLcholesterol,triglycer-
ides, heart rate, fasting C-peptide,
proinsulin and insulin, 2-h insulin, and
M/I in men and women and for 2-h glu-
cose in men. When M/I was added to the
regression model, associations between
ESR and fasting proinsulin in men and
women and HDL cholesterol, 2-h glucose,
andfastingC-peptideinmenbecamestatis-
tically nonsigniﬁcant. Associations be-
tween ESR and HDL cholesterol, heart
rate, fasting, and 2-h insulin in men and
women and between ESR and fat mass in
women remained signiﬁcant after adjust-
ment for M/I and waist circumference.
WBC, ESR, and fasting insulin
compared with M/I
Correlations between WBC and fasting
insulin were stronger than those between
WBC and M/I for both men (0.28,
Table 1—WBC and ESR values for general, lifestyle, and clinical characteristics according to the lowest versus highest quartiles of WBC
and ESR
Men Women
All
WBC ESR WBC ESR
3 lowest
quartiles
Highest
quartile
3 lowest
quartiles
Highest
quartile
3 lowest
quartiles
Highest
quartile
3 lowest
quartiles
Highest
quartile
n 441 146 440 140 540 176 535 176 1,313
General characteristics
Age (years) 43.6 41.8 42.8 44.2* 44.7 43.0* 43.7 46.1* 43.8  8.3
Family history of diabetes (%) 25 33 25 33 28 29 25 37 27
Lifestyle characteristics
Frequency of smoking (%) 20 51† 27 30 19 46† 27 21 27
Alcohol intake (g/week)‡ 80 70 81 62 30 39 35 26§ 49 (90)
Clinical characteristics
Waist circumference (cm) 92.9 95.3§ 92.4 97.2§ 80.9 81.9§ 79.8 84.9§ 86.6  12.8
Fat mass (kg) 18.4 20.6§ 18.1 21.7§ 22.3 23.4§ 21.6 25.8§ 20.9  8.9
HDL cholesterol (mmol/l) 1.3 1.1§ 1.3 1.1§ 1.6 1.5§ 1.6 1.5§ 1.4  0.4
Triglycerides (mmol/l)‡ 1.0 1.3§ 1.0 1.3§ 0.8 0.9§ 0.8 0.9§ 0.9 (0.6)
SBP (mmHg) 123 120 122 122 113 113 113 114 117  12
DBP (mmHg) 77 76 76 77 73 73§ 72 74 74  8
Heart rate (bpm) 65 71§ 65 70§ 70 72 69 72§ 68  10
Fasting glucose OGTT (mmol/l)† 5.2 5.3 5.2 5.2 4.9 5.0 4.9 5.0 5.1 (0.7)
2-h glucose OGTT (mmol/l)‡ 5.5 5.6 5.5 5.7 5.5 5.8§ 5.6 5.7 5.6 (1.9)
Fasting C-peptide (pmol/l) 542 669§ 555 634§ 497 561§ 493 569§ 540  232
Fasting proinsulin (pmol/l)‡ 6.0 7.0§ 6.0 7.0§ 5.0 5.0 5.0 6.0§ 6.0 (4.0)
Fasting insulin OGTT (pmol/l)‡ 31 42§ 30 41§ 27 35§ 27 37§ 31 (23)
2-h insulin (pmol/l)‡ 126 160§ 125 160§ 151 181§ 148 210§ 148 (155)
M/I (mol   min
	1 kgFFM
	1  
nmol
	1   l
	1)‡
114 96§ 117 91§ 146 144 151 129§ 130 (88)
DataaremeansSD,medians(interquartilerange),orfrequencies.*Statisticallysigniﬁcantdifference(P0.05)frommeanin3lowestquartiles(linearregression
analysis,adjustedforsmokingandstudycenter)†Statisticallysigniﬁcantdifference(P0.05)fromproportioninthreelowestquartiles(logisticregressionanalysis,
adjusted for sex, age, and study center). ‡Median. §Statistically signiﬁcant difference (P  0.05) from mean/median in 3 lowest quartiles (linear regression analysis,
adjusted for sex, age, smoking, and study center).
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0.01). Per unit increase in WBC, fasting
insulin increased by 8.1% (95% CI 5.4–
10.8) in men and by 9.8% (7.3–12.3) in
women. When we adjusted for waist cir-
cumference and M/I, the increase was
4.1% (1.7–6.4) in men and 7.0% (4.8–
9.1)inwomen.Withadjustmentforwaist
circumference and fasting insulin, the de-
crease per unit of WBC in M/I became
statistically nonsigniﬁcant in both men
(–1.8% [95% CI 	0.5 to 4.0]) and
women (–0.7% [	2.8 to 1.4]).
In men, the correlation between ESR
and M/I was somewhat stronger than the
correlationbetweenESRandfastinginsu-
lin(0.23,P0.01).Inwomen,itwas
the other way around (0.26, P 
0.01). Per unit increase in ESR, fasting
insulin increased by 2.2% (95% CI 1.4–
3.0) in men and 1.5% (1.0–2.0) in wom-
en; adjusted for waist circumference and
M/I, the increase was 0.9% (0.3–1.6) in
men and 0.6% (0.2–1.0) in women. With
adjustment for waist circumference and
fastinginsulin,thedecreaseperunitWBC
in M/I was 0.7% (0.1–1.4) in men and
0.6% (0.2–1.0) in women.
Additional analyses
To examine whether the associations be-
tween WBC, ESR, and fasting C-peptide
andproinsulincouldbeexplainedbyfast-
ing insulin, we added fasting insulin to
regression model 1. Results showed that
associationsbetweenWBC,ESR,andpro-
insulin and between ESR and C-peptide
disappeared in both men and women.
However, the association between WBC
and fasting C-peptide remained (stan-
dardized  in men 0.094 and in women
0.075).
Twenty-threeparticipantshadaWBC
10  10
12/l, and 190 participants had
an ESR value 15 mm/h. Exclusion of
highWBCandESRvalueshadsomeeffect
on the size of the correlations with the
cardiometabolic variables. However, ex-
ceptforthecorrelationbetweenWBCand
fasting C-peptide in men (P  0.07) and
correlations between ESR and SBP (P 
0.07) and DBP (P  0.07) in women, all
of the reported correlations remained sta-
tistically signiﬁcant.
CONCLUSIONS — In a large, healthy
European cohort, we found that two gen-
eral markers of inﬂammation, WBC and
ESR, were associated with insulin sensi-
tivity, as measured by the hyperinsuline-
mic-euglycemic clamp, and with a wide
range of other cardiometabolic risk fac-
tors. Insulin resistance was related to sev-
eral inﬂammatory factors previously
(2,6,7). However, in these studies, fasting
insulinwasoftenusedasasurrogatemea-
sure of insulin resistance (6,7). We have
now shown that insulin sensitivity as
measured by the standard technique, the
Table 2—Spearman rank correlations and standardized regression coefﬁcients for the associations between WBC and cardiometabolic
risk factors
Correlation Model 1 Model 2 Model 3 Model 4
Men
Waist circumference (cm) 0.15* 0.157† — 0.096† —
Fat mass (kg) 0.19* 0.198† 0.062† 0.131† 0.047
HDL cholesterol (mmol/l) 	0.32* 	0.294† 	0.243† 	0.245† 	0.219†
Triglycerides (mmol/l) 0.23* 0.221† 0.158† 0.163† 0.126†
sBP (mmHg) 	0.08 	0.045 	0.090† 	0.051 	0.083
dBP (mmHg) 0.01 	0.020 	0.059 	0.041 	0.064
Heart rate (bpm) 0.24* 0.231† 0.205† 0.177† 0.166†
Fasting glucose OGTT (mmol/l) 	0.03 0.009 	0.020 0.019 	0.003
2-h glucose OGTT (mmol/l) 0.06 0.102† 0.065 0.072 0.063
Fasting C-peptide (pmol/l) 0.25* 0.243† 0.173† 0.170† 0.132†
Fasting proinsulin (pmol/l) 0.21* 0.173† 0.109† 0.096 0.063
Fasting insulin OGTT (pmol/l) 0.28* 0.259† 0.182† 0.171† 0.128†
2-h insulin (pmol/l) 0.18* 0.217† 0.158† 0.136† 0.119†
M/I 	0.19* 	0.227† 	0.150† — —
Women
Waist circumference (cm) 0.12* 0.162† — 0.109† —
Fat mass (kg) 0.11* 0.175† 0.047† 0.125† 0.044
HDL cholesterol (mmol/l) 	0.19* 	0.186† 	0.137† 	0.150† 	0.123†
Triglycerides (mmol/l) 0.14* 0.157† 0.119† 0.127† 0.108†
sBP (mmHg) 	0.02 0.050 0.008 0.031 0.004
dBP (mmHg) 0.04 0.095† 0.048 0.076 0.047
Heart rate (bpm) 0.14* 0.122† 0.110† 0.121† 0.118†
Fasting glucose OGTT (mmol/l) 0.04 0.081 0.033 0.071 0.034
2-h glucose OGTT (mmol/l) 0.08* 0.133† 0.109† 0.109† 0.100†
Fasting C-peptide (pmol/l) 0.20* 0.241† 0.172† 0.200† 0.163†
Fasting proinsulin (pmol/l) 0.11* 0.148† 0.097† 0.098† 0.072
Fasting insulin OGTT (pmol/l) 0.27* 0.301† 0.225† 0.256† 0.215†
2-h insulin (pmol/l) 0.16* 0.204† 0.171† 0.163† 0.151†
M/I 	0.10* 	0.154† 	0.115† — —
Model 1 adjusted for age, center, and smoking status; model 2 adjusted for age, center, smoking status, and waist circumference; model 3 adjusted for age, center,
smoking status, and M/I; and model 4 adjusted for age, center, smoking status, waist circumference, and M/I. *Statistically signiﬁcant correlation (P  0.05).
†Statistically signiﬁcant standardized regression coefﬁcient (P  0.05).
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associated with inﬂammation. In addi-
tion, we have shown that fasting hyperin-
sulinemia is independently and at least as
strongly associated with inﬂammation as
insulin resistance. The RISC study previ-
ously showed that insulin resistance and
hyperinsulinemia are independent con-
tributors to cardiovascular risk (9). The
present results are supported by Festa et
al. (11), who showed that fasting proinsu-
lin and insulin were related to ﬁbrinogen
andplasminogenactivatorinhibitor1inde-
pendently of insulin resistance as estimated
by an intravenous glucose tolerance test.
When we adjusted for waist circum-
ference, the associations between WBC,
ESR, and insulin resistance were reduced
but remained strong. A number of proin-
ﬂammatory cytokines are known to di-
rectly affect insulin sensitivity: tumor
necrosis factor-
 and leptin have been
shown to affect insulin sensitivity in ani-
mal models, whereas IL-6 has been
shown to induce insulin resistance in hu-
mans (12–14). Hypothetically, the in-
ﬂammatory effect on fasting insulin
concentrations could occur in the liver.
Fasting hyperinsulinemia has been sug-
gested to reﬂect insulin resistance in the
liver (15). IL-6 has been shown to inhibit
insulin signaling in hepatocytes (16). Be-
cause of the cross-sectional nature of our
data, a reversed pathway is also possible:
the state of insulin resistance and/or hy-
perinsulinemia itself promotes inﬂamma-
tion. Insulin has an anti-inﬂammatory
effect in that it can lessen the acute-phase
response(17).Insulinresistancemaypre-
vent the anti-inﬂammatory effect of insu-
lin. Another possibility is that low-grade
inﬂammation, insulin resistance, and hy-
perinsulinemia are all manifestations of
another underlying pathological condi-
tion, for example, dysfunction of the au-
tonomicnervoussystemasaconsequence
of a disturbed food and activity behavior
pattern. This dysfunction has been hy-
pothesized to underlie the metabolic syn-
drome and its precursors (18).
However, an indirect pathway from
inﬂammation to insulin resistance via
obesity could also be possible. A body of
evidence shows that obesity causes in-
ﬂammation. However, some data suggest
the reverse to also be true: a state of
chronic inﬂammation may be a causative
factor in obesity (19).
Besides insulin sensitivity and fasting
insulin, both WBC and ESR showed con-
sistent and strong associations with waist
circumference,fatmass,HDLcholesterol,
triglycerides,heartrate,and2-hinsulinin
men and women. Associations between
WBC,ESR,and2-hglucoseanddBPwere
less consistent, and we found no associa-
tions between WBC, ESR, and sBP and
fasting glucose. The strong relations be-
tween WBC, ESR, and the several cardio-
Table 3—Spearman rank correlations and standardized regression coefﬁcients for the associations between ESR and cardiometabolic
risk factors
Correlation Model 1 Model 2 Model 3 Model 4
Men
Waist circumference (cm) 0.24* 0.186† — 0.095† —
Fat mass (kg) 0.22* 0.194† 0.048 0.102† 0.034
HDL cholesterol (mmol/l) 	0.17* 	0.121† 	0.076 	0.032 	0.023
Triglycerides (mmol/l) 0.19* 0.171† 0.121† 0.102† 0.082
sBP (mmHg) 	0.03 	0.013 	0.063 	0.038 	0.067
dBP (mmHg) 	0.04 0.002 	0.040 	0.041 	0.060
Heart rate (bpm) 0.18* 0.180† 0.151† 0.139† 0.130†
Fasting glucose OGTT (mmol/l) 	0.02 	0.029 	0.048 	0.039 	0.045
2-h glucose OGTT (mmol/l) 0.13* 0.110† 0.069 0.020 0.032
Fasting C-peptide (pmol/l) 0.12* 0.130† 0.053 0.038 0.012
Fasting proinsulin (pmol/l) 0.08 0.122† 0.033 	0.002 	0.026
Fasting insulin OGTT (pmol/l) 0.23* 0.231† 0.144† 0.134† 0.100†
2-h insulin (pmol/l) 0.19* 0.199† 0.145† 0.080† 0.075†
M/I 	0.27* 	0.231† 	0.145† — —
Women
Waist circumference (cm) 0.24* 0.198† — 0.142† —
Fat mass (kg) 0.24* 0.227† 0.070† 0.173† 0.065†
HDL cholesterol (mmol/l) 	0.18* 	0.181† 	0.113† 	0.127† 	0.083†
Triglycerides (mmol/l) 0.18* 0.112† 0.061 0.068 0.039
SBP (mmHg) 	0.09* 0.005 	0.054 	0.009 	0.052
DBP (mmHg) 	0.08* 0.008 	0.059 	0.013 	0.059
Heart rate (bpm) 0.17* 0.145† 0.128† 0.124† 0.116†
Fasting glucose OGTT (mmol/l) 	0.05 	0.002 	0.056 	0.003 	0.048
2-h glucose OGTT (mmol/l) 0.14* 0.062 0.027 0.006 0.001
Fasting C-peptide (pmol/l) 0.19* 0.153† 0.055 0.082† 0.022
Fasting proinsulin (pmol/l) 0.17* 0.124† 0.036 0.044 	0.009
Fasting insulin OGTT (pmol/l) 0.26* 0.234† 0.136† 0.148† 0.090†
2-h insulin (pmol/l) 0.26* 0.217† 0.179† 0.133† 0.120†
M/I 	0.21* 	0.218† 	0.161† — —
Model 1 adjusted for age, center, and smoking status; model 2 adjusted for age, center, smoking status, and waist circumference; model 3 adjusted for age, center,
smoking status, and M/I; and model 4 adjusted for age, center, smoking status, waist circumference, and M/I. *Statistically signiﬁcant correlation (P  0.05).
†Statistically signiﬁcant standardized regression coefﬁcient (P  0.05).
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smallerbutdidnotconsistentlydisappear
afteradjustmentforinsulinresistance.Al-
though the data are cross-sectional, they
suggest that a state of chronic low-grade
inﬂammation does not lead to the devel-
opment of a pattern of high cardiometa-
bolic risk via the inducement of insulin
resistance. Instead, the associations seem
to be of a direct nature. Most are sup-
ported by the literature. Infection and in-
ﬂammation are well known to be
associated with marked changes in lipid
and lipoprotein metabolism (20). An as-
sociation between subclinical inﬂamma-
tionandelevatedheartratewasfoundina
study of middle-aged and elderly individ-
uals without apparent heart disease (21).
Interestingly, we also found an associa-
tionbetweenWBCandfastingC-peptide,
which did not disappear after adjustment
for fasting insulin. A direct effect of in-
ﬂammation on C-peptide is not known.
However, because our observations are
not of a prospective nature, the direction
of the associations could also be reversed.
C-peptide has been found to induce
monocyte chemotaxis in vitro and may
play an active role in atherogenesis (22).
Another association that could be re-
versed is that of inﬂammation and lipids.
Evidenceforadirecteffectoflipidsonthe
induction of a proinﬂammatory state is
increasing. Among other studies, one in
which healthy men were subjected to a
water test and a 6-h fat challenge showed
that after the fat challenge, neutrophil
counts and activation of monocytes and
neutrophils were increased compared
with values after the water test (23).
The relationship between smoking,
alcohol, and inﬂammation has long been
known. Our study results conﬁrm the
majoreffectthatsmokingbehaviorhason
inﬂammation: the number of smokers
more than doubled in the highest quartile
of WBC values compared with the num-
bers in lower quartiles. Results from the
present study also conﬁrm that the use of
alcohol reduces inﬂammation.
Our study has a number of limita-
tions. Both WBC and ESR were not cen-
trally determined by a single laboratory,
possibly inducing measurement variabil-
ity. Systematic differences between study
centers were observed, but we adjusted
for study center in all analyses. Another
drawback is that we had no information
on possible infections in our participants
that could have caused a high WBC or
ESR. However, removal of the clinically
abnormal values of WBC and ESR had no
major effect on the correlations between
these markers and cardiometabolic vari-
ables. Also, WBC and ESR may be viewed
as suboptimal markers of inﬂammation
comparedwiththecurrentlyverypopular
marker CRP (which we did not measure).
However, both WBC and ESR have fre-
quently been shown to be associated with
cardiometabolic abnormalities and with
the development of cardiometabolic dis-
ease and cardiovascular mortality
(2–5,24,25). A further limitation is that
because of the cross-sectional nature of
our data, we can draw no conclusions on
causality and directionality of the associ-
ations we found. Finally, in observational
studies,theinterpretationoftheobserved
associationsandthechangesinthemodel
after addition of additional variables is
limited by chance and by imprecision of
the measurements. In the present study,
effortsweremadetoperformprecisemea-
surements of insulin resistance. Further-
more,allcenterswerecentrallyinstructed
on the measurements and central labora-
tories performed most assays. The consis-
tent pattern observed—that the majority
oftheassociationsbetweentheinﬂamma-
tion markers and cardiometabolic risk
factors remained strong after addition of
M/I to the model and regression coefﬁ-
cients only slightly decreased—suggests
that insulin resistance is not a large inter-
mediary factor.
Besides the limitations, our study has
some major advantages. First, we mea-
sured inﬂammatory markers in a large
number of healthy participants. Second,
we measured insulin sensitivity with the
goldstandardtechnique.Finally,wemea-
sured a wide variety of cardiometabolic
riskfactors,rangingfromglucoseconcen-
trations to concentrations of C-peptide.
In conclusion, this study showed that
low-grade chronic inﬂammation is
strongly associated with cardiometabolic
riskinahealthypopulation.Insulinresis-
tance, as measured by the hyperinsuline-
mic-euglycemicclamp,seemstobeoneof
these cardiometabolic risk factors rather
thananintermediaryfactorintherelation
between inﬂammation and other cardio-
metabolic risk factors.
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